A phase I feasibility trial of a live, genetically modified Salmonella typhimurium bacillus (VNP20009) for the treatment of cancer by intra-tumoral injection

Study title: 
A phase I feasibility trial of a live, genetically modified Salmonella typhimurium bacillus (VNP20009) for the treatment of cancer by intra-tumoral injection
Date receipt dossier: 
25 jun 1999
Pharmaceutical study code: 
CLI-007
Company / Sponsor: 
Vion Pharmaceuticals, Inc.
Phase: 
I
Treated organism: 
Humans
Indication category: 
Cancer therapy
Disease: 
Non-hematologic malignancies
Therapeutic approach: 
Tumor colonization
Genetic modification: 
Not relevant
Method of transfer of nucleic acid of interest: 
Not relevant
Administered biological material: 
Genetically modified Salmonella typhimurium bacillus
Route of administration: 
Intratumoral
Locations in Belgium: 
Universitair Ziekenhuis Gasthuisberg, Leuven
Type of procedure: 
Contained use only
Notes: 
Trial never started in Belgium